1. Home
  2. CLLS vs ATOM Comparison

CLLS vs ATOM Comparison

Compare CLLS & ATOM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cellectis S.A.

CLLS

Cellectis S.A.

SELL

Current Price

$0.97

Market Cap

103.8M

Sector

Health Care

ML Signal

SELL

Logo Atomera Incorporated

ATOM

Atomera Incorporated

HOLD

Current Price

$2.06

Market Cap

117.5M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
CLLS
ATOM
Founded
1999
2001
Country
France
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Semiconductors
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
103.8M
117.5M
IPO Year
2014
2016

Fundamental Metrics

Financial Performance
Metric
CLLS
ATOM
Price
$0.97
$2.06
Analyst Decision
Buy
Analyst Count
5
0
Target Price
★ $4.45
N/A
AVG Volume (30 Days)
55.6K
★ 669.5K
Earning Date
11-12-2026
10-29-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 4.41
EPS
★ N/A
N/A
Revenue
N/A
★ $62,000.00
Revenue This Year
N/A
$361.54
Revenue Next Year
N/A
$233.33
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$0.88
$1.99
52 Week High
$5.45
$12.37

Technical Indicators

Market Signals
Indicator
CLLS
ATOM
Relative Strength Index (RSI) 37.12 27.59
Support Level N/A N/A
Resistance Level $1.28 $3.51
Average True Range (ATR) 0.12 0.24
MACD 0.00 -0.04
Stochastic Oscillator 0.00 2.02

Price Performance

Historical Comparison
CLLS
ATOM

About CLLS Cellectis S.A.

Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.

About ATOM Atomera Incorporated

Atomera Inc is engaged in the business of developing, commercializing, and licensing proprietary processes and technologies for the semiconductor industry. The company's technology, named Mears Silicon Technology, or MST, is a thin film of re-engineered silicon, typically 100 to 300 angstroms (or approximately 20 to 60 silicon atomic unit cells) thick. MST can be applied as a transistor channel enhancement to CMOS-type transistors, the majority of widely used in the semiconductor industry. The company's silicon technology can be used for applications like Analog, DRAM, logic, processors, and SRAM. Geographically, it generates maximum revenue from North America.

Share on Social Networks: